CU20150066A7 - Compuestos tricíclicos para inhibir el canal cftr - Google Patents

Compuestos tricíclicos para inhibir el canal cftr

Info

Publication number
CU20150066A7
CU20150066A7 CUP2015000066A CU20150066A CU20150066A7 CU 20150066 A7 CU20150066 A7 CU 20150066A7 CU P2015000066 A CUP2015000066 A CU P2015000066A CU 20150066 A CU20150066 A CU 20150066A CU 20150066 A7 CU20150066 A7 CU 20150066A7
Authority
CU
Cuba
Prior art keywords
pharmaceutically acceptable
tricyclic compounds
cftr channel
inhibit
acceptable salt
Prior art date
Application number
CUP2015000066A
Other languages
English (en)
Inventor
Mahbub Ahmed
Alexander Ashall-Kelly
Louisa Gueritz
Jeffrey Mckenna
Joseph Mckenna
Simon Mutton
Rakesh Parmar
Jon Shepherd
Paul Wright
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50030372&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CU20150066(A7) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CU20150066A7 publication Critical patent/CU20150066A7/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención proporciona compuestos tricíclicos heterocíclicos sustituidos de la fórmula (I) o una sal farmacéuticamente aceptable del mismo ESPACIO PARA FÓRMULA activos como inhibidores del canal CFTR, y útiles en el tratamiento de enfermedad poliquística del riñón y diarrea secretora. La presente invención proporciona una composición farmacéutica que comprende una cantidad terapéuticamente efectiva de un compuesto tricíclico heterocíclico sustituido o una sal farmacéuticamente aceptable del mismo, y uno o más vehículos farmacéuticamente aceptables.
CUP2015000066A 2012-12-19 2015-06-19 Compuestos tricíclicos para inhibir el canal cftr CU20150066A7 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261739335P 2012-12-19 2012-12-19
US201361906141P 2013-11-19 2013-11-19
PCT/IB2013/061043 WO2014097148A1 (en) 2012-12-19 2013-12-17 Tricyclic compounds for inhibiting the cftr channel

Publications (1)

Publication Number Publication Date
CU20150066A7 true CU20150066A7 (es) 2015-11-27

Family

ID=50030372

Family Applications (1)

Application Number Title Priority Date Filing Date
CUP2015000066A CU20150066A7 (es) 2012-12-19 2015-06-19 Compuestos tricíclicos para inhibir el canal cftr

Country Status (25)

Country Link
US (2) US20140171417A1 (es)
EP (1) EP2935278B1 (es)
JP (1) JP6284546B2 (es)
KR (1) KR20150097660A (es)
CN (1) CN105143230B (es)
AP (1) AP2015008539A0 (es)
AR (1) AR094122A1 (es)
AU (1) AU2013365739A1 (es)
BR (1) BR112015014292A2 (es)
CA (1) CA2895660A1 (es)
CL (1) CL2015001730A1 (es)
CR (1) CR20150325A (es)
CU (1) CU20150066A7 (es)
EA (1) EA201591177A1 (es)
ES (1) ES2628369T3 (es)
HK (1) HK1209741A1 (es)
IL (1) IL239389A0 (es)
MX (1) MX2015007939A (es)
PE (1) PE20151055A1 (es)
PH (1) PH12015501386A1 (es)
SG (1) SG11201504594QA (es)
TN (1) TN2015000279A1 (es)
TW (1) TW201429974A (es)
UY (1) UY35211A (es)
WO (1) WO2014097148A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6165733B2 (ja) 2011-09-16 2017-07-19 ノバルティス アーゲー Ｎ−置換ヘテロシクリルカルボキサミド類
KR20150097660A (ko) 2012-12-19 2015-08-26 노파르티스 아게 Cftr 채널을 억제하기 위한 트리시클릭 화합물
CA2895656A1 (en) * 2012-12-19 2014-06-26 Novartis Ag Tricyclic compounds as cftr inhibitors
TWI686429B (zh) * 2014-09-19 2020-03-01 美商摩曼帝夫特性材料公司 用於經控制之矽氧烷交聯的鉑(ii)二烯錯合物
LT3286198T (lt) * 2015-04-23 2021-07-12 Trevi Therapeutics, Inc. Junginiai, skirti gydyti niežulio būkles
CN106478558B (zh) * 2016-10-17 2019-03-29 天津雅奥科技发展有限公司 一种4-羟甲基-二氢-呋喃-2(3h)-酮的合成方法
EP3911649A1 (en) * 2019-01-17 2021-11-24 F. Hoffmann-La Roche AG A process for the preparation of tetrahydropyridopyrimidines
KR20220046544A (ko) * 2019-06-12 2022-04-14 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 답즙산 설사를 치료하는 방법
CA3216614A1 (en) 2021-04-29 2022-11-03 Lydia BOIKE Deubiquitinase-targeting chimeras and related methods
CN117654560B (zh) * 2023-12-01 2024-06-04 安徽泽升科技股份有限公司 一种通过氧化氨基连续化制备硝基化合物的方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6608098B1 (en) 1999-08-25 2003-08-19 Banyu Pharmaceutical Co., Ltd. Isoindole derivatives
JP2002255967A (ja) 2001-02-27 2002-09-11 Banyu Pharmaceut Co Ltd イソインドール誘導体を有効成分とする糖尿病の治療剤、糖尿病の慢性合併症の予防剤又は肥満の治療剤。
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
MX2009006228A (es) 2006-12-12 2009-06-22 Schering Corp Inhibidores de aspartil proteasa.
WO2009042270A2 (en) * 2007-07-05 2009-04-02 Trustees Of Boston University Reca inhibitors and their uses as microbial inhibitors or potentiators of antibiotic activity
AU2008345225A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
EP2464354B1 (en) * 2009-08-10 2015-04-01 The Regents of The University of California Pyrimido-pyrrolo-quinoxalinedione inhibitors of cystic fibrosis transmembrane conductance regulator protein and uses therefor
USRE48842E1 (en) 2011-05-27 2021-12-07 The Regents Of The University Of California Pyrimido-pyrrolo-oxazine-dione compound inhibitors of the cystic fibrosis transmembrane conductance regulator protein and uses therefor
KR20150097660A (ko) 2012-12-19 2015-08-26 노파르티스 아게 Cftr 채널을 억제하기 위한 트리시클릭 화합물
CA2895656A1 (en) * 2012-12-19 2014-06-26 Novartis Ag Tricyclic compounds as cftr inhibitors

Also Published As

Publication number Publication date
SG11201504594QA (en) 2015-07-30
PE20151055A1 (es) 2015-08-05
PH12015501386A1 (en) 2015-09-02
US20150336986A1 (en) 2015-11-26
CR20150325A (es) 2015-08-10
JP6284546B2 (ja) 2018-02-28
EP2935278A1 (en) 2015-10-28
MX2015007939A (es) 2016-03-11
IL239389A0 (en) 2015-07-30
EA201591177A1 (ru) 2015-11-30
JP2016509579A (ja) 2016-03-31
KR20150097660A (ko) 2015-08-26
TW201429974A (zh) 2014-08-01
TN2015000279A1 (en) 2016-10-03
US20140171417A1 (en) 2014-06-19
CN105143230A (zh) 2015-12-09
US9359381B2 (en) 2016-06-07
AU2013365739A1 (en) 2015-07-09
CL2015001730A1 (es) 2015-08-28
ES2628369T3 (es) 2017-08-02
HK1209741A1 (en) 2016-04-08
AP2015008539A0 (en) 2015-06-30
CN105143230B (zh) 2017-06-09
WO2014097148A1 (en) 2014-06-26
BR112015014292A2 (pt) 2017-07-11
WO2014097148A9 (en) 2015-02-19
CA2895660A1 (en) 2014-06-26
UY35211A (es) 2014-07-31
EP2935278B1 (en) 2017-03-15
AR094122A1 (es) 2015-07-08

Similar Documents

Publication Publication Date Title
UY39630A (es) Inhibidores de bromodominios
CU24397B1 (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b
MX2019004626A (es) Compuesto de piridona como inhibidor de c-met.
CR20150078A (es) Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
CR20130487A (es) 1,3-oxazinas como inhibidores de BACE1 y/o BACE2
NI201600058A (es) Compuestos derivados de piridilo bicíclicos fusionados a anillo como inhibidores de fgfr4
CO6620055A2 (es) Ciertas amino-pirimidinas, composiciones de las mismas y métodos para el uso de los mismos
DOP2016000085A (es) Amino-heteroaril-benzamidas como inhibidores de cinasa
CL2013002417A1 (es) Compuestos derivados de fluoropiridinona; composición farmacéutica que los comprende; y su uso en el tratamiento de infecciones bacterianas.
MX2016006336A (es) Compuestos pirazolopirimidina.
CU24350B1 (es) DERIVADOS DE 5-HETEROARIL-4-FENIL-4,5-DIHIDROPIRROLO(3,4-c)PIRAZOL-6-ONA ACTIVOS COMO INHIBIDORES DE BET
CR20150418A (es) Compuestos de tetrahidropirrolotiazina
DOP2015000201A (es) Compuestos de azabencimidazol como inhibidores de pde4 isoenzimas para el tratamiento del snc y otros trastornos
CR20110634A (es) Inhibidores de fosfoinositida 3 cinasa y/ u objetivo mamifero de rapamicina
ECSP12011799A (es) Compuestos de espiropiperidina y uso farmacéutico de los mismos
CR20140361A (es) Inhibidores de pde9 con estructura básica de imidazotriazinona
MX374513B (es) Compuestos de morfolinona de ácido heteroarilo como inhibidores mdm2 para el tratamiento de cáncer.
UY34960A (es) Dihidropiridona p1 como inhibidores del factor xia
UY32490A (es) Inhibidores de beta-secretasa
CR20140036A (es) Compuesto inhibidor de la señalización de la trayectoria notch
CU20160192A7 (es) Derivados de indano e indolina útiles como activadores de la guanilato ciclasa soluble
EA202090098A1 (ru) Фармацевтические композиции терапевтически активных соединений
PE20150128A1 (es) Moduladores del transporte nuclear y usos de los mismos
CR20150325A (es) Compuestos trcíclicos para inhibir el canal cftr
UY35325A (es) Derivados sustituidos del ácido bisfenil butanóico fosfónico como inhibidores de la nep